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Abstract
Background: Angiopoietin growth factors (Angs) regulate angiogenesis and lymphangiogenesis by binding to the
endothelial Tie2 receptor. Ang2 expression is elevated in tissue hypoxia and inflammation, which also induce cleavage
of the extracellular domain of the orphan Tie1 receptor. Here we have examined if the concentrations of Ang2 and the
soluble extracellular domain of Tie1 in patient plasma are associated with the prognosis of patients with metastatic
breast cancer.
Methods: Plasma Tie1 and Ang2 levels were measured in metastatic breast cancer patients treated in a phase II trial
with a taxane-bevacizumab combination chemotherapy in the first-line treatment setting. They were analyzed before
treatment, after 6 weeks and 6months of treatment, and at the final study visit. Using the median concentrations as
cutoffs, Tie1 and Ang2 data were dichotomized into low and high concentration groups. Additionally, we analyzed
Tie1 concentrations in plasma from 10 healthy women participating in a breast cancer primary prevention study.
Results: Plasma samples were available from 58 (89%) of the 65 patients treated in the trial. The baseline Tie1 levels of
the healthy controls were significantly lower than those of the metastatic patients (p < 0.001). The overall survival of
the patients with a high baseline Tie1 level was significantly shorter (multivariate HR 3.07, 95% CI 1.39–6.79, p = 0.005).
Additionally, the progression-free survival was shorter for patients with a high baseline Tie1 level (multivariate HR 3.78,
95% CI 1.57–9.09, p = 0.003). In contrast, the baseline Ang2 levels had no prognostic impact in a multivariate Cox
proportional hazard regression analysis. The combined analysis of baseline Tie1 and Ang2 levels revealed that patients
with both high Tie1 and high Ang2 baseline levels had a significantly shorter overall survival than the patients with low
baseline levels of both markers (multivariate HR for overall survival 4.32, 95% CI 1.44–12.94, p = 0.009).
Conclusions: This is the first study to demonstrate the prognostic value of baseline Tie1 plasma concentration in
patients with metastatic breast cancer. Combined with the results of the Ang2 analyses, the patients with both high
Tie1 and Ang2 levels before treatment had the poorest survival.
Trial registration: Clinicaltrials.gov: NCT00979641, registration date 19-DEC-2008. The regional Ethics Committee:
R08142M, registration date 18-NOV-2008.
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Background
Several drugs targeting the vascular endothelial growth
factor (VEGF) and VEGF receptors (VEGFR) are currently
used as treatment of various cancer types in clinics [1].
VEGF targeting antibodies alleviate age-related macular
degeneration, but in cancer therapy, they provide only
limited benefits. For this reason, a significant interest has
emerged in the targeting of the more recently character-
ized Ang/Tie endothelial growth factor system, which has
essential functions in embryonic development, the regen-
eration of the mature vasculature, tissue inflammation
and tumor angiogenesis [2–6]. Angiopoietin growth fac-
tors (Ang1–4) bind to the Tie2 receptor. The homologous
Tie1 protein does not bind angiopoietins directly, al-
though it participates in the Ang-Tie2 signal transduction
complex [2, 6–8].
Ang1 stabilizes the vasculature after angiogenesis and
is a more potent Tie2 agonist than Ang2, which can act
as an agonist or antagonist of the Tie2 receptor, depend-
ing on a number of other factors [9–11]. In normal
homeostasis, Ang2 levels are low, but the Ang2/Ang1
ratio is increased in inflamed tissues, e.g. in sepsis and in
malignancies, including breast cancer [12, 13]. High Ang2
levels are associated with poor patient survival in multiple
malignancies, breast cancer among others [14–19]. Some
of the Ang/Tie system targeted antibodies have already
been evaluated in clinical trials, but so far, the effects of
anti-Ang2 monotherapy have been modest [20–22]. A
better understanding of Ang function is clearly needed for
the rational development of effective Ang-pathway tar-
geted therapies. Although Tie1 expression in endothelial
cells is increased in tumor vessels and deletion of the Tie1
gene in tumor-bearing mice decreased tumor growth and
angiogenesis in preclinical experiments [4, 23], the signifi-
cance of Tie1 in tumor progression is also unclear. Tie1
ectodomain cleavage occurs in vivo in association with
acute [11] and chronic inflammation [24], leading to in-
creased concentration of the soluble extracellular domain
in the serum of patients with severe viral infections [11].
Furthermore, Tie1 deletion in a murine metastasis model
tightened endothelial barrier and therefore, reduced meta-
static foci [25].
In the present study, we investigated the prognostic
value of the circulating levels of Tie1 and Ang2 in pa-
tients who received first-line taxane-bevacizumab com-
bination -chemotherapy combination for the treatment
of metastatic breast cancer. Additionally, we explored if
a combined analysis of Tie1 and Ang2 levels would help
to identify the patients with poor prognosis in need of
novel treatment approaches.
Methods
All together 65 patients with histologically verified
HER2-negative advanced breast cancer were enrolled
into the single-arm, prospective, phase 2 study in three
Finnish university cancer clinics between May 2009 and
October 2013 (NCT00979641). The method of patient
recruitment, the study design and the clinical trial results
were previously published [26]. Briefly, patients included
in the study received a taxane (paclitaxel 90mg/m2 on
days 1, 8 and 15 or docetaxel 50mg/m2 on days 1 and 15)
with bevacizumab (10mg/kg on days 1 and 15) on a treat-
ment cycle of 4 weeks as the first-line chemotherapy for
metastatic breast cancer. Docetaxel was given to 32 pa-
tients and 33 patients received paclitaxel.
Bevacizumab 15mg/kg every three weeks was continued
as maintenance therapy for those patients with non-pro-
gressive disease after taxane discontinuation. In addition
to bevacizumab, patients with hormone receptor-positive
disease received endocrine therapy. Furthermore, bevaci-
zumab could be continued with second-line chemother-
apy. All patients provided written informed consent and
the regional Ethics Committee approved the study proto-
col (R08142M).
Blood samples were obtained from the patients during
treatment. EDTA samples for plasma analysis were
obtained at the baseline, every 6 weeks during the bev-
acizumab-taxane combination, at the discontinuation of
taxane treatment, during the bevacizumab maintenance
therapy, first every three weeks for the first two months
and thereafter every 12 weeks, and at the final study visit.
Healthy control samples were obtained from 10 women
participating in a mammography screening program at
the Hatanpää Breast Clinic in Tampere. These women vol-
untarily participated in a breast cancer primary prevention
study currently in progress at the University of Tampere
and, as a part of the accepted protocol, blood samples
were drawn for scientific purposes. All participants gave
their written informed consent and the regional Ethics
Committee approved the study (R15023).
Measurement of plasma Tie1 and Ang2 levels by ELISA
assay
Tie1 and Ang2 levels were measured in patient plasma
samples using a modified hTie1 and hAng2 ELISA
protocol (R&D Systems Europe Ltd., Abingdon, UK,
Duoset, DY5907 and DY623, respectively). Briefly, a 96-
well plate was coated with 100 μl of diluted capture anti-
body (1:180 in PBS) per well and incubated o/n at room
temperature (RT). The wells were washed three times
with PBS-0.05% Tween 20, followed by blocking with
300 μl/well of the Reagent Diluent 2 (R&D, Y995) for
1.5 h at RT on an orbital shaker for Tie1 or with 250 μl/
well of 1% BSA in PBS for 1 h at RT for Ang2. The wells
were washed 3 x with PBS-0.05% Tween 20. For Tie1,
50 μl/well of the reagent RD1–89 (R&D, DILUENT08)
was added. Standards and samples diluted in the RD5–
17 reagent (R&D, RD508) were pipetted into the wells at
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100 μl/well and incubated for 2 h at RT on an orbital
shaker. For Ang2, 100 μl of a sample or standards in di-
luent reagent (1% BSA in PBS) was added to the wells,
and incubated for 2 h at RT. The wells were washed 3 x
with PBS-0.05% Tween 20 and 100 μl of detection anti-
body diluted 1:180 in diluent reagent (Reagent Diluent 2,
R&D, for Tie1, 1% BSA in PBS for Ang2) was added and
incubated for 2 h at RT on an orbital shaker for Tie1
and for 1.5 h at RT for Ang2. After washing 3 x with
PBS-0.05% Tween 20, 100 ul of SA-HRP solution per
well (in Reagent Diluent 2 for Tie1, and in 1% BSA in
PBS for Ang2) was added before incubating for 20 min
at RT. The wells were washed 3 x with PBS-0.05% Tween
20. Then a mixture of Color Reagent A and Color Reagent
B for Tie1 (R&D, DY999) and BioFX®TMB substrate solu-
tion for Ang2 (SurModics, Eden Prairie, MN, USA) was
added at 100 μl/well and incubated for 20min in the dark
at RT. Stop solution (50 μl of 1M HCl) was added, and
the absorbance of each well was measured within 20–30
min using a microplate reader with the filter set to 450
nm and the correction wavelength set to 540 nm. The
interassay coefficients of variation for Tie1 and Ang2 were
11.4 and 7.1%, respectively.
Patient characteristics
The patient population and the analyzed plasma samples
were identical to our previous paper focusing on plasma
interleukin-8 levels as a prognostic marker [27]. At the
baseline, plasma samples were available from 53 patients
(82%). Overall, plasma samples were available from 58
(89%) of the 65 patients treated in the study. Key charac-
teristics of the study population and the main efficacy
outcomes are presented in Table 1. Plasma samples for
Tie1 and Ang2 were analyzed at four time points: at the
baseline, six weeks after the treatment initiation, six
months after the treatment initiation and at the final
visit. The number of patients that had plasma samples
analyzed and the reasons for exclusions are presented in
a flow chart (Fig. 1). Six weeks’ and six months’ samples
were available only for those patients that were still on
study treatment at that time point.
The median progression-free survival (PFS) and overall
survival (OS) were similar for patients treated with doce-
taxel or paclitaxel (PFS: p = 0.47, OS: p = 0.77). The median
OS for patients with triple-negative breast cancer was 17.9
months (95% CI 8.5–26.9). Furthermore, the median OS
for patients with hormone receptor positive metastatic
breast cancer was 45.0months (95% CI 30.2–51.3).
The mean age of the ten healthy controls was 57.8
years (range 54–67).
Statistical analysis
The statistical plan for the biomarker analysis was ex-
ploratory. Tie1 and Ang2 were dichotomized as low or
high for each patient using the median value as the cut-
off. Sensitivity, specificity and area under curve (AUC)
for plasma Tie1 concentration were determined using
receiver operator characteristic (ROC) analysis. Baseline
Tie1 or Ang2 levels as independent prognostic factors
(below/above median) were evaluated using Cox propor-
tional hazard regression analysis. Multivariate analysis
was performed using the Cox model, and it was adjusted
by age (continuous), menopausal status (yes/no), hormone
receptor status (negative/positive), presence of visceral
metastasis (yes/no), number of metastatic lesions (cut-off
of three metastatic lesions) and extent of the disease (cut-
off of three metastatic sites). The Mann-Whitney U test
Table 1 Baseline characteristics and the efficacy outcomes of
the plasma biomarker population compared to the overall study
population
Plasma biomarker
population (n = 58)
Overall study
population (n = 65)
Age, years
Median (range) 58 (32–75) 57 (32–75)
Menopausal status, n (%)
Pre-menopausal 9 (15.5) 10 (15.4)
Post-menopausal 49 (84.5) 55 (84.6)
History of early stage disease,
n (%)
52 (89.7) 57 (87.7)
Disease free interval, n (%)
≤ 24months 10 (19.2) 11 (19.3)
> 24 months 42 (80.8) 46 (80.7)
Hormone receptor status, n (%)
ER+ and/or PR+ 47 (81.0) 53 (81.5)
ER- and PR- 11 (19.0) 12 (18.5)
Number of metastatic lesions, n (%)
≤ 3 11 (19.0) 14 (21.5)
> 3 47 (81.0) 51 (78.5)
Extent of disease
< 3 sites 36 (62.1) 39 (60.0)
≥ 3 sites 22 (37.9) 26 (40.0)
Site of metastatic disease, n (%)
Visceral disease 46 (79.3) 53 (81.5)
Non-visceral disease 12 (20.7) 12 (18.5)
Median overall survival,
months (95% CI)
37.5 (25.4–49.6) 35.1 (22.2–50.3)
Median progression-free
survival, months (95% CI)
11.3 (8.3–14.4) 11.3 (9.7–16.0)
Response to treatment
Complete response/partial
response
38 (71.7) 40 (61.5)
Stable disease 13 (24.5) 15 (23.1)
Progressive disease 2 (3.8) 3 (4.6)
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was used to compare differences in the baseline Tie1 and
Ang2 levels between groups with different baseline char-
acteristics. The Wilcoxon signed rank test was used to
compare between baseline and week 6 plasma Tie1 and
Ang2 levels. P-values under 0.05 were considered statisti-
cally significant. Statistical analyses were performed using
SPSS version 23 statistical software package (SPSS Inc.,
Chicago, IL, USA).
Results
Tie1 and Ang2 plasma levels
For the study population, the median Tie1 level at base-
line was 21.0 ng/ml (95% CI 17.8–23.3, Fig. 2a), and the
median Ang2 level at baseline was 1.29 ng/ml (95% CI
1.03–1.52, Fig. 2b). The baseline Tie1 levels were signifi-
cantly lower in the healthy controls than in the meta-
static breast cancer patients (Fig. 2a). The median Tie1
level for healthy controls was 12.8 ng/ml (95% CI 10.4–
16.5, Fig. 2a). The most optimal cut-off value (16.0 ng/ml)
for plasma Tie1 concentration had a sensitivity of 77.4%,
but a specificity of only 30.0%, for distinguishing metastatic
breast cancer patients from healthy controls with an AUC
0.917 (95% CI 0.839–0.995, p < 0.001).
There were no statistically significant differences in
baseline Tie1 or Ang2 levels between groups with differ-
ent baseline characteristics, including menopausal status
(p = 0.09 for Tie1, p = 0.13 for Ang2), hormone receptor
status (p = 0.80 for Tie1, p = 0.14 for Ang2), number of
metastatic lesions (p = 0.69 for Tie1, p = 0.37 for Ang2)
or visceral disease (p = 0.92 for Tie1, p = 0.15 for Ang2).
Only the patients with more than three metastatic sites
had significantly higher baseline Tie1 levels than the pa-
tients with fewer metastatic sites (median Tie1 23.7 ng/ml,
95% CI 21.0–29.0 vs. 17.8 ng/ml, 95% CI 16.0–21.1, p =
0.002). Similarly, the patients with more than three
metastatic sites had significantly higher baseline Ang2
levels (median Ang2 1.08 ng/ml, 95% CI 0.66–1.36 vs.
1.54 ng/ml, 95% CI 1.23–2.29, p = 0.008).
Differences in Tie1 and Ang2 concentrations between
baseline and week six samples were analyzed to evaluate
the treatment effect. The median baseline Tie1 level was
21.0 ng/ml (95% CI 17.8–23.3), which was significantly
higher than the median Tie1 level at six weeks (15.4 ng/ml
[95% CI 14.1–17.1], p < 0.001, Fig. 2a). The median de-
crease in the Tie1 level between these two time points was
22.9% (95% CI 20.9–27.4). The median baseline Ang2
level was 1.29 ng/ml (95% CI 1.03–1.52) and the median
Ang2 level at six weeks was 0.62 ng/ml (95% CI 0.57–
0.84). The median decrease in the levels of Ang2 from the
baseline to six weeks, 47.0% (95% CI 34.5–52.9), was also
statistically significant (p < 0.001, Fig. 2b).
Effect of Tie1 or Ang2 levels on survival
Median progression-free survival was longer for patients
in the low baseline Tie1 level group than for the patients
in the high baseline Tie1 group (Fig. 3a, Table 2). No dif-
ference was observed in progression-free survival in rela-
tion to baseline Ang2 levels (Fig. 3b, Table 2).
The overall survival was significantly shorter for pa-
tients with a high baseline Tie1 concentration (Fig. 3c,
Table 3). Additionally, patients with high baseline Ang2
levels had shorter overall survival when analyzed by the
age-adjusted Cox hazard regression model (Table 3).
However, in a multivariate Cox model adjusted by age,
menopausal status, hormone receptor status, presence of
visceral metastases, number of metastatic lesions and ex-
tent of disease, a high baseline levels of Ang2 alone was not
a significant factor for poor prognosis (Fig. 3d, Table 3).
Effect of combined analysis of Tie1 and Ang2 levels on
survival
For progression-free survival, the combined analysis of
baseline Tie1 and Ang2 levels did not add any value
compared to the Tie1 analysis on its own (Fig. 4a, Table 2).
However, the combined analysis for high or low baseline
Fig. 1 Flow diagram of study patient plasma samples analyzed at
baseline, after six weeks’ treatment, after six months’ treatment and
at final visit. Final plasma samples were taken at the final study visit
and the reasons for discontinuation are presented in the chart
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Tie1 and Ang2 levels was more effective in the selection of
patients with better overall survival (Fig. 4b, Table 3). The
median overall survival for patients with low baseline levels
of both Tie1 and Ang2 was 46.8months (95% CI 23.8–
79.8). In contrast, the median overall survival for patients
with high baseline levels of both Tie1 and Ang2 was only
21.5months (95% CI 8.8–34.7).
Changes in plasma tie 1 or Ang2 levels and prognosis
The median decline in Ang2 levels between baseline and
week six was 47.0%. The patients with Ang2 level de-
cline higher than the median value had significantly
worse prognoses. Multivariate Hazard Ratio (HR) for
overall survival was 4.53 (95% CI 1.82–11.27, p = 0.001).
In contrast, a high Tie1 decline during the first six weeks
of treatment was not prognostic. The median Tie1 decline
during this time period was 22.9%. The patients had simi-
lar survival whether they had Tie1 decline higher or lower
than median value between baseline and week six (multi-
variate HR for overall survival 1.04, 95% CI 0.46–2.33, p =
0.921).
Only seven patients, i.e. 14% of the patients whose
final samples were available, had at least 30% increased
Tie1 plasma concentrations at their final visits, when
compared to the previous measurements in each patient.
For all these patients, the reason for study discontinu-
ation was disease progression. Nevertheless, these pa-
tients had a similar overall survival as the patients with
stable or declining Tie1 levels (multivariate HR 2.30,
95% CI 0.90–5.85, p = 0.078). At least 30% increased
Ang2 concentration was observed in 24 patients at their
final visits (48% of the patients whose final samples were
available). The overall survival of these patients was
significantly worse than in the patients with stable or
declining Ang2 values (multivariate HR 2.17, 95% CI
1.09–4.31, p = 0.027).
Discussion
The baseline concentration of the extracellular fragment
of the orphan Tie1 receptor in bevacizumab plus tax-
ane-treated breast carcinoma patients was found to be
associated with both their overall survival and their pro-
gression-free survival (multivariate HR for overall sur-
vival 3.07, 95% CI 1.39–6.79, p = 0.005, multivariate HR
for progression-free survival 3.78, 95% CI 1.57–9.09, p =
0.003). Previous studies have reported strong Tie1 ex-
pression in malignant tissues, including breast cancer
[23, 28–30]. In gastric cancer, patients with Tie1 expres-
sion in their formalin-embedded tissue specimens had
worse survival than the patients without Tie1 expression
[30]. However, the prognostic value of circulating Tie1
levels has not been previously studied in malignant
diseases.
Metastatic breast cancer patients had significantly higher
baseline plasma Tie1 levels than the healthy controls (p <
0.001). However, circulating Ang2 levels are known to be
higher on cancer patients [31] and therefore, we did not
analyze plasma Ang2 levels on healthy controls.
Previous studies have indicated that the high concen-
tration of the circulating Tie2 ligand Ang2 is associated
with poor patient prognosis [16–19], and Ang2/Tie sys-
tem-targeting antibodies and tyrosine kinase inhibitors
are currently in clinical trials, including in those focused
on breast cancer [20, 22]. In our study however, the
a b
Fig. 2 Plasma Tie1 and Ang2 levels. a Tie1 levels of healthy controls compared to the Tie1 levels of patients with metastatic breast cancer at
baseline and at week six after treatment. b Ang2 levels of patients with metastatic breast cancer at baseline and at week six after treatment.
mBCa =metastatic breast cancer
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baseline Ang2 level was not a significant prognostic
marker for either progression-free survival or overall
survival. However, it has been reported that an increase
in serum Ang2 concentration during anti-VEGF treat-
ment contributes to acquired drug resistance [32]. In
our study, for the final plasma samples, a cut-off point
of 30% was chosen because it was considered as a clinic-
ally meaningful change. In half of the patients of our
study, the Ang2 plasma concentration was the highest at
their final visit, and these patients had poor overall sur-
vival (multivariate HR 2.17, 95% CI 1.09–4.31, p =
0.027), perhaps because of increased acquired tumor
chemoresistance [32].
Targeting of both Tie1 and Ang2 would be an interest-
ing trial approach in the future for the treatment of
breast cancer. In our study, high baseline Tie1 and Ang2
concentrations were associated with median overall sur-
vival of only 21.5 months (95% CI 8.8–34.7). This was
significantly less than in the patients who had low
plasma concentrations of both Tie1 and Ang2 (46.8
months, 95% CI 23.8–79.8, p = 0.009). Interestingly,
additive inhibition of tumor growth was observed when
angiopoietin activity was blocked in Tie1-deficient mice
[4]. The possible synergistic effect of dual inhibition of
Tie1 and Ang2 might be due to Ang2 influencing earlier
phase in tumor growth than Tie1 [25].
a b
c d
Fig. 3 Progression-free survivals and overall survivals grouped by baseline plasma Tie1 or Ang2 levels a Progression-free survival for patients with
high or low plasma Tie1 at baseline. b Progression-free survival for patients with high or low plasma Ang2 at baseline. c Overall survival for patients
with high or low plasma Tie1 at baseline. d Overall survival for patients with high or low plasma Ang2 at baseline. Cox regression analysis adjusted by
age, menopausal status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions and extent of the disease
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According to our study, high baseline Tie1 level ap-
pears to be the best way to find the patients with short
progression-free survival. In fact, the baseline Ang2 level
and the combined analysis of Tie1 and Ang2 baseline
levels do not provide additional information in terms of
progression-free survival compared to Tie1 levels alone.
The Tie1 levels in healthy individuals were lower than
in patients with metastatic disease before chemotherapy.
During the bevacizumab and taxane therapy, the Tie1
levels declined substantially. However, the decline in
Tie1 concentration was not related to the patient sur-
vival. Only the decrease in Ang2 concentration was
prognostic, with a multivariate hazard ratio of 4.53 (95%
CI 1.82–11.27, p = 0.001).
Bevacizumab has been investigated in several phase III
trials as treatment of metastatic breast cancer. However,
none of the trials has proven overall survival advantage for
patients treated with bevacizumab [33]. Therefore, bevaci-
zumab in only recommended for the treatment of highly
selected patients with a need of a tumor response more
commonly achieved with bevacizumab [33, 34]. All of our
study patients were treated with bevacizumab. However,
the effect of bevacizumab to Tie1 levels remains unex-
plored in this study. However, the main finding of our study
was the prognostic value of pretreatment circulating Tie1
levels and bevacizumab did not confound this analysis.
Although, to our knowledge, this is the first study to
evaluate the prognostic role of plasma Tie1 levels in
Table 3 Cox regression analysis for overall survival
N n Overall survival
Age-adjusted HR [95% CI] p value multivariate HRa [95% CI] p value
Baseline Tie1
Low 27 15 1 1
High 26 24 2.82 [1.41–5.66] 0.003 3.07 [1.39–6.79] 0.005
Baseline Ang2
Low 27 15 1 1
High 26 24 2.33 [1.20–4.54] 0.012 1.58 [0.72–3.46] 0.246
Combined analysis
Tie1 and Ang2 low 18 8 1 1
Tie1 low, Ang2 high 9 7 2.21 [0.78–6.25] 0.135 1.34 [0.42–4.22] 0.612
Tie1 high, Ang2 low 9 7 2.77 [0.95–8.09] 0.062 2.73 [0.88–8.46] 0.080
Tie1 and Ang2 high 17 17 4.79 [1.93–11.90] 0.001 4.32 [1.44–12.94] 0.009
Abbreviations: N number of patients, n number of events, HR hazard ratio, CI confidence interval. Statistically significant results are highlighted in bold
aHazard ratio adjusted by age, menopausal status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions and extent of
the disease
Table 2 Cox regression analysis for progression-free survival
N n Progression-free survival
Age-adjusted HR [95% CI] p value multivariate HRa [95% CI] p value
Baseline Tie1
Low 27 16 1 1
High 26 15 2.13 [1.02–4.46] 0.043 3.78 [1.57–9.09] 0.003
Baseline Ang2
Low 27 14 1 1
High 26 17 1.21 [0.59–2.47] 0.597 1.22 [0.54–2.77] 0.620
Combined analysis
Tie1 and Ang2 low 18 9 1 1
Tie1 low, Ang2 high 9 7 1.27 [0.47–3.43] 0.632 1.16 [0.39–3.39] 0.783
Tie1 high, Ang2 low 9 5 3.86 [1.18–12.57] 0.025 4.45 [1.25–15.79] 0.021
Tie1 and Ang2 high 17 10 2.02 [0.80–5.07] 0.133 3.88 [1.25–12.06] 0.019
Abbreviations: N number of patients, n number of events, HR hazard ratio, CI confidence interval. Statistically significant results are highlighted in bold
aHazard ratio adjusted by age, menopausal status, hormone receptor status, presence of visceral metastasis, number of metastatic lesions and extent of
the disease
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breast cancer patients, the study has some limitations.
Our study is a single-arm study with no control arm,
and thus, the impact of bevacizumab on patient survival
and the Tie1 and Ang2 concentrations during therapy
cannot be evaluated. Furthermore, the study population
size is limited, and therefore, our findings must be vali-
dated in a larger patient cohort.
Although immunohistochemical staining of Tie1 in
tumor samples is associated with poor patient survival
in breast cancer [35], the availability of tissue samples
from metastatic tumors varies depending on tumor loca-
tion, tumor load and the clinical need to accept the
complication risks and discomfort related to needle aspi-
rations. Circulating prognostic markers are more useful,
and thus, high baseline circulating Tie1 and Ang2 levels
before and during the treatment can be an additional
way to identify patients with poor prognoses in this patient
population, regardless of standard clinical characteristics.
Most such patients do not derive a long-term benefit from
the current chemotherapy treatment options. Novel treat-
ment approaches, for example immunotherapies, are enter-
ing the clinics for many malignant diseases, and patients
with poor prognoses should increasingly be referred to clin-
ical trials. In preclinical studies, anti-angiogenic drugs and
immune checkpoint inhibitors have demonstrated synergis-
tic benefits [36], and they should be further studied in pro-
spective clinical trials.
Conclusions
High baseline plasma Tie1 level is a promising prognos-
tic marker for both poor progression-free survival and
for poor overall survival in metastatic breast patients
treated with bevacizumab-taxane combination. The pre-
dictive value of circulating Tie1 levels should be evalu-
ated in prospective clinical trials.
Abbreviations
Ang: Angiopoietin; Ang2: Angiopoietin-2; CI: Confidence interval; HR: Hazard
ratio; RT: Room temperature; VEGF: Vascular endothelial growth factor;
VEGFR: Vascular endothelial growth factor receptor
Acknowledgements
We thank Riitta Kauppinen and Heini Sood for their excellent technical assistance.
The authors would like to thank the study patients for their consent to participate
in the study and the study nurses and Irja Kolehmainen for their contributions to
the study.
Authors’ contributions
LT analyzed and interpreted the data and wrote the manuscript. KA
suggested the study. EAK, and VML designed and performed the Tie1
analysis. MH and EM performed the Ang2 analysis. TL contributed to the
statistical data analysis. MT, OL, PV, AJ, PK and PLKL planned the original
clinical study design and treated the patients in the study. PLKL and SA were
responsible for the breast cancer primary prevention study and provided the
healthy control samples. PLKL, the principal investigator, was responsible for
the study design, interpreted the data and revised the manuscript. All
authors read, revised and approved the final manuscript.
Funding
This work was funded by the Pirkanmaa Hospital District Science Center and
Seppo Nieminen funds (LT, PLKL), the Sigrid Juselius Foundation (KA), the
Cancer Society of Finland (KA) and the Orion Research Foundation (EAK).
Ang2 analysis was supported financially by Roche Inc. (PLKL). The design of
the study, collection, analysis and interpretation of the data was done solely
by the authors. The authors were also exclusively responsible for writing the
manuscript.
a
b
Fig. 4 Progression-free survival and overall survival grouped by
combined analysis of baseline plasma Tie1 and baseline plasma Ang2
levels. a Progression-free survival and b Overall survival for patients with
high or low baseline Tie1 and Ang2. Cox regression analysis adjusted by
age, menopausal status, hormone receptor status, presence of visceral
metastasis, number of metastatic lesions and extent of the disease. ap-
value between Tie1 low, Ang2 low and Tie1 low, Ang2 high, bp-value
between Tie1 low, Ang2 low and Tie1 high, Ang2 low, cp-value between
Tie1 low, Ang2 low and Tie1 high, Ang2 high
Tiainen et al. BMC Cancer          (2019) 19:732 Page 8 of 10
Availability of data and materials
The datasets used and analyzed during the current study are available from
the corresponding author upon reasonable request.
Ethics approval and consent to participate
The Ethics Committee of Tampere University Hospital approved the study
protocol (R08142M). The trial identifier is NCT00979641. All study patients
gave their written informed consent. In addition, the participants in the
breast cancer primary prevention study gave their written informed consent
for their blood samples to be used for scientific purposes, and this study was
also approved by the Ethics Committee of Tampere University Hospital
(R15023).
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Oncology, Faculty of Medicine and Health Technology,
Tampere University and Tays Cancer Centre, P.O. Box 100, FI-33014 Tampere,
Finland. 2Department of Oncology, Tampere University Hospital, P.O. Box
2000, FI-33521 Tampere, Finland. 3Wihuri Research Institute and Translational
Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, P.O. Box
63, FI-00014 Helsinki, Finland. 4Research, Development and Innovation
Centre, Tampere University Hospital and Faculty of Medicine and Health
Technology, Tampere University, P.O. Box 2000, FI-33521 Tampere, Finland.
5The Immunopharmacology Research Group, Faculty of Medicine and Health
Technology, Tampere University and Tampere University Hospital, P.O. Box
100, FI-33014 Tampere, Finland. 6Department of Oncology and Radiotherapy,
Turku University Central Hospital, P.O. Box 52, 20521 Turku, Finland.
7Department of Oncology and Radiotherapy, Medical Research Center Oulu,
Oulu University Hospital and University of Oulu, P.O. Box 10, 90029 OYS Oulu,
Finland.
Received: 20 September 2018 Accepted: 19 July 2019
References
1. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor
therapy. Nat Rev Drug Discov. 2016;15:385–403.
2. Augustin HG, Young Koh G, Thurston G, Alitalo K. Control of vascular
morphogenesis and homeostasis through the angiopoietin–tie system.
Nat Rev Mol Cell Biol. 2009;10:165–77.
3. Saharinen P, Jeltsch M, Santoyo MM, Leppänen V-M, Alitalo K. The TIE
receptor family. In: Wheeler DL, editor. Yarden Y, editors. Receptor Tyrosine
Kinases: Family and Subfamilies. Springer International Publishing; 2015. p.
743–75.
4. D’Amico G, Korhonen EA, Anisimov A, Zarkada G, Olopainen T, Hägerling R,
et al. Tie1 deletion inhibits tumor growth and improves angiopoietin
antagonist therapy. J Clin Invest. 2014;124:824–34.
5. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the
ANG2/TIE2 Axis inhibits tumor growth and metastasis by impairing
angiogenesis and disabling rebounds of proangiogenic myeloid cells.
Cancer Cell. 2011;19:512–26.
6. Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin–
TIE pathway. Nat Rev Drug Discov. 2017;16:635–61.
7. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell
Res. 2013;319:1271–80.
8. Saharinen P, Kerkelä K, Ekman N, Marron M, Brindle N, Lee GM, et al.
Multiple angiopoietin recombinant proteins activate the Tie1 receptor
tyrosine kinase and promote its interaction with Tie2. J Cell Biol. 2005;169:
239–43.
9. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C,
et al. Angiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo
Angiogenesis. Science. 1997;277:55–60.
10. Leppänen V-M, Saharinen P, Alitalo K. Structural basis of Tie2 activation and
Tie2/Tie1 heterodimerization. Proc Natl Acad Sci. 2017;114:4376–81.
11. Korhonen EA, Lampinen A, Giri H, Anisimov A, Kim M, Allen B, et al. Tie1
controls angiopoietin function in vascular remodeling and inflammation.
J Clin Invest. 2016;126:3495–510.
12. David S, Mukherjee A, Ghosh CC, Yano M, Khankin EV, Wenger JB, et al.
Angiopoietin-2 may contribute to multiple organ dysfunction and death in
sepsis*. Crit Care Med. 2012;40:3034–41.
13. Staton CA, Hoh L, Baldwin A, Shaw L, Globe J, Cross SS, et al. Angiopoietins
1 and 2 and Tie-2 receptor expression in human ductal breast disease.
Histopathology. 2011;59:256–63.
14. Li P, He Q, Luo C, Qian L. Diagnostic and prognostic potential of serum
angiopoietin-2 expression in human breast cancer. Int J Clin Exp Pathol.
2015;8:660–4.
15. Sfiligoi C, De Luca A, Cascone I, Sorbello V, Fuso L, Ponzone R, et al.
Angiopoietin-2 expression in breast cancer correlates with lymph node
invasion and short survival. Int J Cancer. 2003;103:466–74.
16. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, et al.
Angiopoietin-2 levels are associated with disease progression in metastatic
malignant melanoma. Clin Cancer Res. 2009;15:1384–92.
17. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky
TC, et al. Identification of serum angiopoietin-2 as a biomarker for clinical
outcome of colorectal cancer patients treated with bevacizumab-containing
therapy. Br J Cancer. 2010;103:1407–14.
18. Lam SW, Nota NM, Jager A, Bos MMEMEM, van den Bosch J, van der Velden
AMTT, et al. Angiogenesis- and hypoxia-associated proteins as early
indicators of the outcome in patients with metastatic breast Cancer given
first-line bevacizumab-based therapy. Clin Cancer Res. 2016;22:1611–20.
19. Hacker UT, Escalona-Espinosa L, Consalvo N, Goede V, Schiffmann L, Scherer SJ,
et al. Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from
the randomised phase III AVAGAST trial. Br J Cancer. 2016;114:855–62.
20. Cascone T, Heymach JV. Targeting the angiopoietin/Tie2 pathway: cutting
tumor vessels with a double-edged sword? J Clin Oncol. 2012;30:441–4.
21. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. Final
results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent
ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and
progression-free survival-2. Gynecol Oncol. 2016;143:27–34.
22. Diéras V, Wildiers H, Jassem J, Dirix LY, Guastalla J-P, Bono P, et al.
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab
as first-line therapy for HER2-negative locally recurrent or metastatic breast
cancer: a phase 2 randomized study. Breast. 2015;24:182–90.
23. Kaipainen A, Vlaykova T, Hatva E, Böhling T, Jekunen A, Pyrhönen S, et al.
Enhanced expression of the tie receptor tyrosine kinase mesenger RNA in
the vascular endothelium of metastatic melanomas. Cancer Res. 1994;54:
6571–7.
24. Kim M, Allen B, Korhonen EA, Nitschké M, Yang HW, Baluk P, et al. Opposing
actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. J Clin
Invest. 2016;126:3511–25.
25. La Porta S, Roth L, Singhal M, Mogler C, Spegg C, Schieb B, et al. Endothelial
Tie1-mediated angiogenesis and vascular abnormalization promote tumor
progression and metastasis. J Clin Invest. 2018;128:834–45.
26. Tiainen L, Tanner M, Lahdenpera O, Vihinen P, Jukkola A, Karihtala P, et al.
Bevacizumab combined with docetaxel or paclitaxel as first-line treatment
of HER2-negative metastatic breast Cancer. Anticancer Res. 2016;36:6431–8.
27. Tiainen L, Hamalainen M, Luukkaala T, Tanner M, Lahdenpera O, Vihinen P, et
al. Low plasma IL-8 levels during chemotherapy are predictive of excellent
long-term survival in metastatic breast Cancer. Clin Breast Cancer. 2019. https://
doi.org/10.1016/j.clbc.2019.03.006. [Epub ahead of print].
28. Yang XH, Hand RA, Livasy CA, Cance WG, Craven RJ. Overexpression of the
receptor tyrosine kinase tie-1 intracellular domain in breast cancer. Tumor
Biol. 2003;24:61–9.
29. Torigata M, Yamakawa D, Takakura N. Elevated expression of Tie1 is
accompanied by acquisition of cancer stemness properties in colorectal
cancer. Cancer Med. 2017;6:1378–88.
30. Lin WC, Li AF, Chi CW, Chung WW, Huang CL, Lui WY, et al. Tie-1 protein
tyrosine kinase: a novel independent prognostic marker for gastric cancer.
Clin Cancer Res. 1999;5:1745–51.
31. Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, et al. The role of
angiopoietins as potential therapeutic targets in renal cell carcinoma. Transl
Oncol. 2014;7:188–95.
32. Rigamonti N, Kadioglu E, Keklikoglou I, Wyser Rmili C, Leow CC, De Palma
M. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling
blockade. Cell Rep. 2014;8:696–706.
Tiainen et al. BMC Cancer          (2019) 19:732 Page 9 of 10
33. Miles DW, Dieras V, Cortes J, Duenne A-A, Yi J, O’Shaughnessy J. First-line
bevacizumab in combination with chemotherapy for HER2-negative
metastatic breast cancer: pooled and subgroup analyses of data from 2447
patients. Ann Oncol. 2013;24:2773–80.
34. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th
ESO-ESMO international consensus guidelines for advanced breast Cancer
(ABC 4)†. Ann Oncol. 2018;29:1634–57.
35. Tseng LM, Hsu CY, Wang HC, Liu JM, Chang HM, Lo SS, et al. Tie-1 tyrosine
kinase is an independent prognostic indicator for invasive breast cancer.
Anticancer Res. 2001;21(3C):2163–70.
36. Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C,
Kiialainen A, et al. Dual angiopoietin-2 and VEGFA inhibition elicits
antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci
Transl Med. 2017;9.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Tiainen et al. BMC Cancer          (2019) 19:732 Page 10 of 10
